Cariban combines 10 mg of doxylamine succinate and 10 mg of pyridoxine hydrochloride in a modified-release capsule. This formulation directly influences the onset time, the antiemetic coverage over the 24-hour period, and tolerance. Here, we detail the pharmacological and clinical points that consumer leaflets most often overlook.
Modified-release of Cariban: how the formulation affects the onset time
Each capsule contains two types of granules: an immediate-release fraction and a prolonged-release fraction. The immediate fraction releases doxylamine and pyridoxine as soon as it passes through the stomach, while the delayed fraction maintains plasma concentrations for several hours.
In practice, the evening dose (two capsules at bedtime) aims to cover morning nausea through a delayed plasma peak. The morning and afternoon capsules complete daytime coverage. Relief is therefore not immediate after the first dose: it generally takes until the next morning to observe a significant clinical effect with the standard dosing regimen.
This kinetics differs from that of double-release tablets like Xonvea or Diclectin (dosed at 20 mg/20 mg), whose formulation allows for a twice-daily dosing with potentially faster onset of action. Cariban, with its 10 mg/10 mg capsules, requires up to four doses per day to achieve comparable coverage. An article detailing the effects of Cariban during pregnancy specifies this difference between the formulations available in France.
Dosing of Cariban: gradual regimen and maximum dose
The recommended dosing regimen in the RCP is based on a gradual titration according to the severity of symptoms:
- Day 1: two capsules at bedtime only, to assess tolerance and effect on the next day’s morning nausea.
- Day 2: if symptoms persist during the day, add one capsule in the morning and one capsule in the mid-afternoon, for a total of four capsules per day.
- Maximum dose: four capsules per day (i.e., 40 mg of doxylamine and 40 mg of pyridoxine), divided into three distinct doses.
The evening dose remains the cornerstone of treatment. The morning and afternoon capsules are added only when the evening dose is insufficient. This regimen is not optional: a patient who starts directly with four capsules exposes herself to marked daytime drowsiness without demonstrated additional antiemetic benefit.
Adverse effects of doxylamine in pregnant women: anticholinergic profile
Doxylamine is a first-generation H1 antihistamine. Its profile of adverse effects is dominated by its anticholinergic and sedative properties, not by fetal toxicity. This is a point we want to emphasize: the fetal safety data of the doxylamine/pyridoxine combination is robust, with a clinical history spanning several decades.
Frequent adverse effects in the mother primarily concern the central nervous system and the autonomic system:
- Drowsiness, sometimes debilitating at the beginning of treatment, which justifies the main dose at bedtime.
- Dry mouth, constipation, urinary retention: classic, dose-dependent anticholinergic signs.
- Dizziness, blurred vision, concentration difficulties, especially in cases of co-prescription with other anticholinergic or sedative medications.
Pyridoxine (vitamin B6) at the dose of 10 mg per capsule does not generate adverse effects specific to the dosages used in Cariban. Its role is to enhance the antiemetic effect of doxylamine, not to correct a deficiency.
Interactions to monitor
The combination with other antihistamines, opioids, benzodiazepines, or alcohol increases sedation. Medications with anticholinergic effects (urinary antispasmodics, certain tricyclic antidepressants) increase the risk of urinary retention and severe constipation. The RCP of Cariban contraindicates co-administration with MAOIs due to the risk of amplifying anticholinergic effects.
International recommendations: doxylamine/pyridoxine as first-line antiemetic
The Green-Top Guidelines BJOG 2024 classify the doxylamine/pyridoxine combination among the first-line H1 antihistamines for nausea and vomiting in pregnancy. This recommendation covers moderate forms such as hyperemesis gravidarum, with a high level of evidence regarding the absence of teratogenicity.
The French marketing authorization for Cariban targets nausea and vomiting of pregnancy that do not respond to hygienic-dietary measures alone. In clinical practice, we observe that treatment is often initiated late, after several weeks of symptoms, due to unfounded fears of a malformative risk. International recommendations emphasize the lack of benefit in delaying the introduction of treatment.
The modified-release capsule of Cariban contains up to 72.7 mg of sucrose per unit. This point, mentioned in the RCP, concerns patients with fructose intolerance, glucose-galactose malabsorption syndrome, or sucrose-isomaltase deficiency. Outside of these rare situations, this excipient does not pose a clinical problem.
Treatment with Cariban continues as long as symptoms persist. There is no defined maximum duration in the RCP, but regular reevaluation remains recommended, especially since pregnancy-related nausea typically decreases spontaneously after the first trimester in the majority of patients.
